US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Number of shares and votes in Orexo

    Uppsala, Sweden – June 29, 2018 – The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of 325,000 class C shares as announced on June 15, 2018. Today, the last trading day of the month, there are in total 35,450,456 shares - whereof 34,560,456 are ordinary shares and 890 000 class C shares - and 34,649,456 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and Lena Wange, IR & Communications ManagerCFO                   Tel: +46 (0)18 780 88 Tel: +46 (0)18 780 88 0000E-mail:

    Number of shares and votes in Orexo

    Uppsala, Sweden – June 30, 2017 – The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of class C shares as announced on June 16, 2017. Today, the last trading day of the month, there are in total 35 104 585 shares - whereof 34,539,585 are ordinary shares and 565 000 class C shares - and 34 596 085 votes in the company. For further information, please contact: Orexo AB (publ.) Henrik Juuel, EVP and CFO Lena Wange, IR & Communications ManagerTel: +46 (0)18 780 88 00 Tel: +46 (0)18 780 88 00E-mail: ir@orexo.com E-mail:

    Number of shares and votes in Orexo

    Uppsala, Sweden – July 31, 2015 – The number of shares and votes in Orexo AB have changed as a result of that the company has repurchased the entire issue of class C shares. Today, the last trading day of the month, there are in total 34,580,810 shares - whereof 34,445,810 are ordinary shares and 135,000 class C shares - and 34,459,310 votes in the company. For further information, please contact:Henrik Juuel, EVP and Chief Financial OfficerTel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About OrexoOrexo is a specialty pharmaceutical company commercializing its proprietary

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media